Barinthus Biotherapeutics' (BRNS) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Barinthus Biotherapeutics (NASDAQ: BRNS) has had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating continued analyst skepticism.
• Despite a slight stock increase of 1.5% to $1.33, the company has demonstrated a challenging performance with a significant earnings miss, reporting ($0.52) per share.
• A hedge fund, HighTower Advisors LLC, has recently acquired a stake in Barinthus Biotherapeutics, purchasing 37,450 shares, which highlights ongoing institutional interest in the company.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.

Barinthus Biotherapeutics Stock Up 1.5%

BRNS stock traded up $0.02 during midday trading on Tuesday, hitting $1.33. The company's stock had a trading volume of 3,456 shares, compared to its average volume of 445,236. Barinthus Biotherapeutics has a 12 month low of $0.64 and a 12 month high of $2.92. The firm has a market capitalization of $54.16 million, a price-to-earnings ratio of -0.77 and a beta of -0.71. The company has a 50 day moving average of $1.24 and a two-hundred day moving average of $1.08.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.23). On average, analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC purchased a new stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 37,450 shares of the company's stock, valued at approximately $36,000. HighTower Advisors LLC owned about 0.09% of Barinthus Biotherapeutics at the end of the most recent quarter. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.